How Gut Health Affects Immune Responses to the Oral Rotavirus Vaccine in Adults in Zambia

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-50
SponsorCentre for Infectious Disease Research in Zambia

About this trial

The Rotavirus SpatioTrasncriptomics (Rota-Omics) study is a multidisciplinary research project aimed at understanding why oral rotavirus vaccines perform less effectively in some low- and middle-income countries, including Zambia. Rotavirus remains one of the leading causes of severe diarrheal disease in infants and young children worldwide, despite the widespread introduction of vaccines such as Rotarix® and Rotavac®. Although these vaccines have greatly reduced childhood deaths in many countries, vaccine effectiveness is often lower in settings where the burden of disease is highest. Understanding the reasons behind this reduced protection is critical for improving child health globally.

A major focus of the study is Environmental Enteropathy (EE), also known as Environmental Enteric Dysfunction (EED), a chronic inflammatory condition of the small intestine that is common in low-resource settings. EE is associated with damage to the intestinal lining, chronic immune activation, poor nutrient absorption, and impaired gut barrier function. These changes are thought to interfere with the body's ability to respond effectively to oral vaccines, which rely on strong intestinal immune responses.

The RotaOmics study uses a systems biology approach to investigate how the immune system, gut microbiome, nutrition, and intestinal inflammation interact to influence rotavirus vaccine responses. The term "omics" refers to advanced technologies that allow researchers to study genes, proteins, microbes, and other biological processes at a large scale. By combining these approaches, the study aims to identify biological markers and immune pathways associated with strong or weak vaccine responses.

The study involves the collection of samples such as blood, stool, saliva, and breast milk from mothers and infants at different time points before and after vaccination. These samples are analysed using laboratory methods including antibody testing, molecular pathogen detection, microbiome sequencing, and immune profiling. The study also evaluates markers of gut inflammation and intestinal health.

One important goal of the project is to identify correlates of protection, which are measurable biological indicators that predict whether a vaccine is likely to protect against disease. Identifying these markers could help guide the development of improved vaccines or supportive interventions to enhance vaccine performance in vulnerable populations.

The study also contributes to a broader understanding of mucosal immunity, which refers to immune responses occurring in the gastrointestinal tract. Since many enteric infections begin in the gut, understanding intestinal immune function is important not only for rotavirus vaccines but also for other oral vaccines and diarrheal diseases.

In addition to its scientific objectives, RotaOmics includes a strong capacity-building component. The project supports training for local scientists, clinicians, and laboratory personnel in areas such as molecular biology, immunology, genomics, bioinformatics, and data analysis. By strengthening local research expertise and infrastructure, the study aims to support long-term scientific development and improve regional capacity for infectious disease research and outbreak response.

Overall, the RotaOmics study seeks to generate new insights into why oral rotavirus vaccines underperform in some settings and to identify strategies that may improve vaccine effectiveness and child health outcomes in Zambia and similar regions worldwide.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Age ≥ 18 years and ≤ 50 years.

Able and willing to provide written informed consent.

Reside within Lusaka district and available for scheduled follow-up.

Willing to undergo two endoscopy procedures with serial sample collection.

Disqualifiers

Pregnant or breastfeeding.

Active gut disease requiring treatment (e.g., active peptic ulcer disease, gastrointestinal bleeding).

Known severe immunodeficiency (HIV with CD4 < 200 cells/mm³, current cancer chemotherapy, systemic corticosteroids equivalent to >20 mg/day prednisolone for >2 weeks).

Severe comorbidities rendering endoscopy unsafe (e.g., severe cardiopulmonary disease, uncontrolled hypertension, oropharyngeal abnormalities).

Trial population

Healthy adults living in Chawama, a densely populated peri-urban setting in proximity to the study recruitment site.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Rotarix®,

    Biological/Vaccine

    This is an infant vaccine, but this study participants in this study will receive a double oral Rotarix dose at baseline as per study design.

Treatment groups

43 Participants
are divided into 1 treatment group
Group A: Consenting healthy adult Participants aged ≥ 18 years and ≤ 50 years1 intervention

Trial outcomes

Primary outcomes

1

Proportion of participants completing all scheduled study procedures

The percentage of enrolled participants who complete all scheduled study visits and protocol-defined procedures.

Time frame
Through study completion, an average of 1 year.
2

Sample Quality Control (QC) Success Rate

The proportion of tissue biopsies that successfully meet the defined technical quality control thresholds required for spatial transcriptomic (ST) processing (e.g., RNA integrity number, tissue structural preservation, and spot sequencing depth).

Time frame
Through study completion, an average of 1 year.
3

Proportion of intestinal biopsy samples meeting predefined quality control thresholds

The percentage of collected intestinal biopsy samples meeting predefined quality control criteria for downstream laboratory analysis, including tissue integrity and adequate sample preservation.

Time frame
Through study completion, an average of 1 year.
4

Pre-analytical Sample Processing Efficiency

The precise duration of time (measured in minutes) recorded from the exact moment of clinical biopsy collection to the successful snap-freezing/cryopreservation of the tissue sample.

Time frame
Periprocedural

Secondary outcomes

1

Clinical Follow-up Retention Rate

The percentage of enrolled study participants who successfully complete all scheduled follow-up clinical visits and specimen collection time points as per the study protocol.

Time frame
Through study completion, an average of 1 year.
2

Regulated Gene Expression Profiles

Identification of differentially expressed genes and pathway spatial modules within histologically mapped regions of interest (ROIs) on Hematoxylin and Eosin-stained tissue architectures, analysed via spatially aware linear mixed-effects models.

Time frame
Baseline, and up to 52 weeks post-enrollment.
3

Correlation of Mucosal Spatial Transcriptomics with Systemic Immunity

The statistical relationship (evaluated using Spearman rank correlation coefficients) between tissue-based spatial gene module scores and external serologic or stool-based mucosal immune biomarkers, adjusted for age, sex, and baseline environmental enteric dysfunction (EED) markers.

Time frame
Baseline, and up to 52 weeks post-enrollment.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Centre for Infectious Disease Research in Zambia

Lead sponsor

Bill and Melinda Gates Foundation

Collaborator